A detailed history of Creative Planning transactions in Abb Vie Inc. stock. As of the latest transaction made, Creative Planning holds 750,811 shares of ABBV stock, worth $132 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
750,811
Previous 717,586 4.63%
Holding current value
$132 Million
Previous $123 Million 20.47%
% of portfolio
0.15%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$163.84 - $199.33 $5.44 Million - $6.62 Million
33,225 Added 4.63%
750,811 $148 Million
Q2 2024

Aug 15, 2024

BUY
$154.79 - $180.76 $431,399 - $503,778
2,787 Added 0.39%
717,586 $123 Million
Q1 2024

May 10, 2024

BUY
$159.82 - $182.1 $5.03 Million - $5.73 Million
31,489 Added 4.61%
714,799 $130 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $2.47 Million - $2.79 Million
17,978 Added 2.7%
683,310 $106 Million
Q3 2023

Nov 16, 2023

BUY
$133.59 - $154.65 $7.32 Million - $8.48 Million
54,826 Added 8.98%
665,332 $99.2 Million
Q2 2023

Jul 21, 2023

BUY
$132.51 - $164.9 $166,167 - $206,784
1,254 Added 0.21%
610,506 $82.3 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $2.38 Million - $2.74 Million
16,426 Added 2.77%
609,252 $97.1 Million
Q4 2022

Feb 10, 2023

BUY
$138.31 - $165.87 $18.6 Million - $22.2 Million
134,121 Added 29.24%
592,826 $95.9 Million
Q3 2022

Nov 03, 2022

BUY
$134.21 - $153.93 $326,532 - $374,511
2,433 Added 0.53%
458,705 $61.6 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $3.43 Million - $4.36 Million
24,906 Added 5.77%
456,272 $69.9 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $3.06 Million - $3.79 Million
23,152 Added 5.67%
431,366 $69.9 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $1.12 Million - $1.41 Million
10,382 Added 2.61%
408,214 $55.3 Million
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $440,815 - $500,391
4,143 Added 1.05%
397,832 $42.9 Million
Q2 2021

Aug 04, 2021

SELL
$105.21 - $117.21 $5.76 Million - $6.41 Million
-54,720 Reduced 12.2%
393,689 $44.3 Million
Q1 2021

Apr 30, 2021

BUY
$102.3 - $112.62 $910,879 - $1 Million
8,904 Added 2.03%
448,409 $48.5 Million
Q4 2020

Jan 29, 2021

BUY
$80.49 - $108.67 $1.48 Million - $1.99 Million
18,327 Added 4.35%
439,505 $47.1 Million
Q3 2020

Nov 05, 2020

BUY
$85.91 - $100.83 $3.04 Million - $3.57 Million
35,371 Added 9.17%
421,178 $36.9 Million
Q2 2020

Jul 23, 2020

BUY
$73.37 - $98.18 $2.2 Million - $2.95 Million
30,050 Added 8.45%
385,807 $37.9 Million
Q1 2020

May 05, 2020

SELL
$64.5 - $97.79 $636,808 - $965,480
-9,873 Reduced 2.7%
355,757 $27.1 Million
Q4 2019

Jan 30, 2020

SELL
$72.13 - $90.25 $558,430 - $698,715
-7,742 Reduced 2.07%
365,630 $32.4 Million
Q3 2019

Nov 01, 2019

SELL
$62.98 - $75.72 $153,104 - $184,075
-2,431 Reduced 0.65%
373,372 $28.3 Million
Q2 2019

Jul 26, 2019

BUY
$65.7 - $83.98 $2.59 Million - $3.31 Million
39,427 Added 11.72%
375,803 $27.3 Million
Q1 2019

Apr 24, 2019

BUY
$77.14 - $90.79 $1.6 Million - $1.88 Million
20,721 Added 6.56%
336,376 $27.1 Million
Q4 2018

Feb 01, 2019

BUY
$77.85 - $96.01 $1.08 Million - $1.34 Million
13,932 Added 4.62%
315,655 $29.1 Million
Q3 2018

Oct 25, 2018

BUY
$88.91 - $98.84 $1.4 Million - $1.55 Million
15,702 Added 5.49%
301,723 $28.5 Million
Q2 2018

Jul 20, 2018

BUY
$89.78 - $106.23 $1.65 Million - $1.95 Million
18,377 Added 6.87%
286,021 $26.5 Million
Q1 2018

Apr 18, 2018

BUY
$92.01 - $123.21 $599,997 - $803,452
6,521 Added 2.5%
267,644 $25.3 Million
Q4 2017

Jan 17, 2018

BUY
$89.56 - $98.21 $1.93 Million - $2.12 Million
21,549 Added 8.99%
261,123 $25.3 Million
Q3 2017

Oct 17, 2017

BUY
$69.85 - $89.22 $16.7 Million - $21.4 Million
239,574
239,574 $21.3 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.